Encainide is a voltage-gated sodium channel blocker used for management of atrial or ventricular fibrillation, atrial flutter, and ventricular tachycardia, that is no longer used due to proarrhythmic adverse effects. All drug products containing encainide hydrochloride.
- Mechanism
- Curator reviewed
Encainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
- Primary indication
- Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.Curator reviewed
- Formula / weight
- C22H28N2O2 · 352.4699 g/mol (avg)
- First approval
- United States, 2008
Resolves to
PJWPNDMDCLXCOM-UHFFFAOYSA-NSMILESCOC1=CC=C(C=C1)C(=O)NC1=CC=CC=C1CCC1CCCCN1CWhat you can answer from here — as of September 21, 2026
Which drugs share a target with Encainide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account